C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2020 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
CCCC on Nasdaq
Shares outstanding
71,366,920
Price per share
$1.91
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
52,538,995
Total reported value
$116,636,299
% of total 13F portfolios
0%
Share change
-2,051,548
Value change
-$3,488,602
Number of holders
96
Price from insider filings
$1.91
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Point72 Asset Management, L.P. 9.9% $50,277,776 22,647,647 Point72 Asset Management, L.P. 17 Oct 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% $20,959,588 +$20,959,588 9,441,256 RA Capital Management, L.P. 17 Oct 2025
Bain Capital Life Sciences Fund II, L.P. 6.2% $13,453,200 6,060,000 BCLS II Equity Opportunities, LP 17 Oct 2025
WASATCH ADVISORS LP 6.8% -34% $10,773,085 -$5,817,712 4,852,741 -35% Wasatch Advisors LP 30 Sep 2025
MORGAN STANLEY 6.7% +26% $7,030,567 +$1,363,928 4,750,383 +24% Morgan Stanley 30 Jun 2025
ORBIMED ADVISORS LLC 5% -23% $7,921,728 -$2,413,704 3,568,346 -23% OrbiMed Capital LLC 30 Sep 2025
BlackRock, Inc. 2.5% $2,513,362 1,756,613 BlackRock, Inc. 30 Jun 2025

As of 30 Sep 2025, 96 institutional investors reported holding 52,538,995 shares of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC). This represents 74% of the company’s total 71,366,920 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) together control 68% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Lynx1 Capital Management LP 9.9% 7,098,133 0% 3.2% $15,757,855
Soleus Capital Management, L.P. 9.9% 7,053,942 +1.1% 0.84% $15,659,751
ORBIMED ADVISORS LLC 7.3% 5,235,146 -23% 0.28% $11,622,024
MORGAN STANLEY 7% 4,972,032 +4.6% 0% $11,037,911
WASATCH ADVISORS LP 6.8% 4,852,741 -35% 0.06% $10,773,085
VANGUARD GROUP INC 4.5% 3,191,557 +5.7% 0% $7,085,256
BANK OF AMERICA CORP /DE/ 2.9% 2,053,162 +2.2% 0% $4,558,019
MILLENNIUM MANAGEMENT LLC 2.7% 1,934,225 +76% 0% $4,293,980
SILVERARC CAPITAL MANAGEMENT, LLC 2.7% 1,897,383 0.61% $4,212,190
BlackRock, Inc. 2.2% 1,595,639 -13% 0% $3,542,318
Bain Capital Life Sciences Investors, LLC 1.6% 1,111,910 0% 0.16% $2,468,440
RENAISSANCE TECHNOLOGIES LLC 1.3% 936,950 -14% 0% $2,080,029
TANG CAPITAL MANAGEMENT LLC 1.3% 900,000 0% 0.08% $1,998,000
TWO SIGMA INVESTMENTS, LP 1.2% 834,726 +22% 0% $1,853,092
TWO SIGMA ADVISERS, LP 1.1% 763,100 -6% 0% $1,694,082
GEODE CAPITAL MANAGEMENT, LLC 1% 725,304 -2.7% 0% $1,610,795
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.72% 515,437 +265% 0% $1,144,270
JACOBS LEVY EQUITY MANAGEMENT, INC 0.71% 503,145 +14% 0% $1,116,982
CITADEL ADVISORS LLC 0.67% 481,449 0% $1,068,817
GOLDMAN SACHS GROUP INC 0.64% 459,893 -48% 0% $1,020,962
Shay Capital LLC 0.59% 420,000 0.17% $932,400
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.49% 350,606 +5.6% 0% $778,345
DIMENSIONAL FUND ADVISORS LP 0.49% 349,289 -19% 0% $775,460
STATE STREET CORP 0.4% 287,373 0% 0% $637,968
Susquehanna Portfolio Strategies, LLC 0.38% 272,053 +114% 0.01% $603,958

Institutional Holders of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 237,293 $453,230 +$59,099 $1.91 2
2025 Q3 52,538,995 $116,636,299 -$3,488,602 $2.22 96
2025 Q2 54,715,914 $78,242,864 -$14,672,718 $1.43 102
2025 Q1 64,100,740 $102,562,013 -$12,577,745 $1.60 113
2024 Q4 64,400,415 $231,841,449 -$9,805,080 $3.60 113
2024 Q3 64,180,724 $365,858,667 +$21,073,945 $5.70 118
2024 Q2 60,887,928 $281,302,982 +$5,545,189 $4.62 114
2024 Q1 58,201,499 $475,505,218 +$93,890,692 $8.17 104
2023 Q4 47,001,017 $265,585,658 +$85,422,229 $5.65 91
2023 Q3 34,671,251 $64,488,483 -$134,435 $1.86 82
2023 Q2 34,220,399 $94,120,957 -$9,383,233 $2.75 96
2023 Q1 37,418,446 $117,492,869 -$15,156,032 $3.14 117
2022 Q4 39,224,213 $231,404,815 -$9,766,681 $5.90 113
2022 Q3 39,456,577 $346,000,579 -$2,524,371 $8.77 115
2022 Q2 39,425,650 $297,247,580 -$39,977,861 $7.54 111
2022 Q1 37,306,180 $904,604,832 +$6,530,479 $24.26 120
2021 Q4 35,893,940 $1,154,835,979 +$16,687,200 $32.20 115
2021 Q3 34,491,766 $1,542,710,693 +$110,759,163 $44.68 110
2021 Q2 31,945,852 $1,209,520,921 +$259,679,873 $37.84 106
2021 Q1 25,097,387 $926,788,055 +$90,401,887 $36.99 83
2020 Q4 22,706,689 $743,535,975 +$718,564,975 $33.13 75